Abiopharma

🔍 PHAN JENNIFER N (Executive)

Company: TIC Solutions, Inc. (TIC)

Report Date: 2026-06-15

Detailed Transactions and Holdings:

• Acquired 23,391 shares of Restricted Stock Units (Derivative)
  Date: 2026-06-15 | Code: A | equity_swap_involved: 0 | shares_owned_after: 23,391.00 | transaction_form_type: 4 | Footnotes: F1, F2, F2
• Acquired 76,023 shares of Restricted Stock Units (Derivative)
  Date: 2026-06-15 | Code: A | equity_swap_involved: 0 | shares_owned_after: 76,023.00 | transaction_form_type: 4 | Footnotes: F1, F3, F3
• Acquired 46,784 shares of Performance-Based Restricted Stock Units (Derivative)
  Date: 2026-06-15 | Code: A | equity_swap_involved: 0 | shares_owned_after: 46,784.00 | transaction_form_type: 4 | Footnotes: F4, F5, F5
• Acquired 11,696 shares of Performance-Based Restricted Stock Units (Derivative)
  Date: 2026-06-15 | Code: A | Expires: 2031-06-15 | equity_swap_involved: 0 | shares_owned_after: 11,696.00 | transaction_form_type: 4 | Footnotes: F4, F6

Footnotes:

• F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock.
• F2: These restricted stock units vest on March 16, 2029.
• F3: These restricted stock units vest in three equal installments on the first through third anniversaries of the grant date (June 15, 2026).
• F4: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock.
• F5: These performance-based restricted stock units have a three-year performance period and to the extent earned will vest on March 16, 2029. The number of shares of Common Stock that will be earned is subject to increase or decrease based on the result of the performance condition.
• F6: These performance-based restricted stock units will vest, subject to the Issuer's Common Stock achieving a specified stock price, on the later of (x) June 15, 2029 and (y) the calendar day following the achievement of such specified stock price prior to the expiration date.